Unveiling the Research Landscape of Triazole-based Aromatase Inhibitors in Breast Cancer: Bibliometric Insights

Abstract

Breast cancer remains a leading cause of death among women, with one life lost approximately every 13 minutes. Postmenopausal women are particularly susceptible to Estrogen Receptor-positive (ER+) breast cancer. Aromatase inhibitors, including letrozole, exemestane, and anastrozole, suppress estrogen synthesis in peripheral tissues, thereby improving survival rates and reducing the risk of recurrence. The Web of Science Core Collection database was searched for literature on triazolebased aromatase inhibitors in breast cancer. Data on countries, institutions, authors, citations, and key terms were analyzed and visualized using VOSviewer and RAWGraphs. A total of 804 relevant publications were identified, showing a marked increase in research activity in recent years. The United States (345 publications; 28,920 citations) and the United Kingdom (196 publications; 16,021 citations) emerged as leading contributors. The Mayo Clinic, Rochester, United States, recorded the highest institutional citation impact (3,540 citations). The upward trend in publications reflects growing global interest in triazole-based aromatase inhibitors, with research output concentrated in a few leading centers in the US and UK. Expanding international collaboration could broaden the clinical evidence base and improve therapeutic accessibility. Advances in molecular design and pharmacokinetic optimization are evident; however, challenges remain in translating laboratory findings to clinical settings, particularly in overcoming drug resistance and addressing variability in patient response. Since 1989, substantial progress has been made in the development of triazolebased aromatase inhibitors for breast cancer. Continued innovation and global collaboration are essential to refine treatment strategies and enhance patient outcomes.